Cyxone AB (publ) (CYXO.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -22.98 Million SEK | 45.87% |
| 2022 | -42.46 Million SEK | 5.69% |
| 2021 | -45.03 Million SEK | 8.1% |
| 2020 | -49 Million SEK | -39.34% |
| 2019 | -35.16 Million SEK | -127.85% |
| 2018 | -15.43 Million SEK | -74.92% |
| 2017 | -8.82 Million SEK | -112.02% |
| 2016 | -4.16 Million SEK | -2468.9% |
| 2015 | -162 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.75 Million SEK | -2.26% |
| 2024 Q1 | -4.64 Million SEK | 33.51% |
| 2023 Q2 | -5.89 Million SEK | 1.31% |
| 2023 Q1 | -5.97 Million SEK | -179.08% |
| 2023 FY | -22.98 Million SEK | 45.87% |
| 2023 Q4 | -6.99 Million SEK | -34.57% |
| 2023 Q3 | -5.19 Million SEK | 11.9% |
| 2022 FY | -42.46 Million SEK | 5.69% |
| 2022 Q3 | -11.27 Million SEK | 11.3% |
| 2022 Q4 | -2.14 Million SEK | 81.01% |
| 2022 Q2 | -12.71 Million SEK | 23.8% |
| 2022 Q1 | -16.67 Million SEK | -19.24% |
| 2021 Q1 | -8.61 Million SEK | 28.36% |
| 2021 Q2 | -11.45 Million SEK | -33.05% |
| 2021 Q3 | -10.97 Million SEK | 4.22% |
| 2021 FY | -45.03 Million SEK | 8.1% |
| 2021 Q4 | -13.98 Million SEK | -27.46% |
| 2020 Q4 | -12.02 Million SEK | 4.65% |
| 2020 Q1 | -10.18 Million SEK | 49.77% |
| 2020 FY | -49 Million SEK | -39.34% |
| 2020 Q2 | -14.18 Million SEK | -39.32% |
| 2020 Q3 | -12.6 Million SEK | 11.13% |
| 2019 Q4 | -20.27 Million SEK | -251.63% |
| 2019 FY | -35.16 Million SEK | -127.85% |
| 2019 Q3 | -5.76 Million SEK | -32.04% |
| 2019 Q2 | -4.36 Million SEK | 8.32% |
| 2019 Q1 | -4.76 Million SEK | -4.87% |
| 2018 Q1 | -2.74 Million SEK | 14.97% |
| 2018 FY | -15.43 Million SEK | -74.92% |
| 2018 Q2 | -3.75 Million SEK | -36.69% |
| 2018 Q3 | -4.39 Million SEK | -16.91% |
| 2018 Q4 | -4.54 Million SEK | -3.44% |
| 2017 Q1 | -1.49 Million SEK | -14.6% |
| 2017 Q2 | -2.58 Million SEK | -73.57% |
| 2017 FY | -8.82 Million SEK | -112.02% |
| 2017 Q3 | -1.51 Million SEK | 41.34% |
| 2017 Q4 | -3.23 Million SEK | -112.82% |
| 2016 Q4 | -1.3 Million SEK | -5.43% |
| 2016 Q1 | -307 Thousand SEK | 0.0% |
| 2016 FY | -4.16 Million SEK | -2468.9% |
| 2016 Q2 | -1.15 Million SEK | -276.87% |
| 2016 Q3 | -1.23 Million SEK | -6.66% |
| 2015 FY | -162 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | 49.806% |
| Biovica International AB (publ) | -124.82 Million SEK | 81.583% |
| Cantargia AB (publ) | -280.02 Million SEK | 91.79% |
| CombiGene AB (publ) | -35.66 Million SEK | 35.543% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -96.857% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -40.194% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 74.848% |
| Fluicell AB (publ) | -26.55 Million SEK | 13.425% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 81.32% |
| Mendus AB (publ) | -101.61 Million SEK | 77.377% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 37.987% |
| I-Tech AB | 20.2 Million SEK | 213.79% |
| Intervacc AB (publ) | -102.85 Million SEK | 77.648% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -89.553% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 288.914% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -28.452% |
| OncoZenge AB (publ) | -15.9 Million SEK | -44.567% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -5148.63% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 94.078% |
| Lipum AB (publ) | -37.17 Million SEK | 38.165% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 90.752% |
| Ziccum AB (publ) | -21.41 Million SEK | -7.365% |
| BioArctic AB (publ) | 229.24 Million SEK | 110.028% |
| Genovis AB (publ.) | 61.5 Million SEK | 137.38% |
| Camurus AB (publ) | 431.44 Million SEK | 105.328% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 87.073% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 59.541% |
| Aptahem AB (publ) | -11.11 Million SEK | -106.868% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 92.607% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 87.205% |
| Kancera AB (publ) | -64.88 Million SEK | 64.572% |
| Saniona AB (publ) | -95.81 Million SEK | 76.006% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 45.553% |
| AcouSort AB (publ) | -17.08 Million SEK | -34.525% |
| Xintela AB (publ) | -54.08 Million SEK | 57.493% |
| Abliva AB (publ) | -95.5 Million SEK | 75.93% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 526.829% |
| Amniotics AB (publ) | -30.87 Million SEK | 25.53% |
| 2cureX AB (publ) | -32.51 Million SEK | 29.304% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -79.21% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 95.069% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 97.236% |
| Biosergen AB | -27.03 Million SEK | 14.972% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -39.133% |
| Corline Biomedical AB | -1.8 Million SEK | -1170.813% |
| NextCell Pharma AB | -41.95 Million SEK | 45.212% |
| Nanologica AB (publ) | -75.15 Million SEK | 69.412% |
| LIDDS AB (publ) | -40.2 Million SEK | 42.822% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 92.968% |
| BioInvent International AB (publ) | -330.3 Million SEK | 93.04% |
| SynAct Pharma AB | -215.81 Million SEK | 89.348% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 47.816% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 3.151% |
| Alzinova AB (publ) | -16.48 Million SEK | -39.496% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 78.965% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 90.772% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -131.51% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 79.714% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -8.999% |
| Simris Alg AB (publ) | -37.3 Million SEK | 38.376% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 84.861% |